No Data
Growth 250 fell for the first time in five days, with declines in Astroscope ETC in Emerging Markets on the 2nd.
The Tokyo Stock Exchange Growth Market 250 Index has declined for the first time in five days. This comes after a continuous rise leading up to the previous day, and as there wasn't aggressive buying ahead of the four-day holiday, the drop was limited. Heartsheed <219A.T> and Astroscale Holdings <186A.T> were down, while QPS Research Institute <5595.T> and GENDA <9166.T> were up. Kaulis <153A.T> hit a consecutive limit high. The stock that crashed completely the previous day, Oltz <260A.T>, made a sharp rebound. Provided by Wealths A.
Growth 250 has risen for four consecutive days, and Sanbio has significantly increased = Emerging Markets, Day 1.
The Tokyo Stock Exchange Growth Market 250 Index has risen for four consecutive days. With limited selling demand during the holiday gap, a gradual upward trend is observed. SanBio <4592.T> has significantly increased, and iSpace <9348.T>, Heartseed <219A.T>, and QPS Research Institute <5595.T> have also risen. Kawaris <153A.T>, which is taking measures against unauthorized logins, reached the maximum increase, and Ortz <260A.T>, which had overstated its results, completely matched for the first time in three business days due to an expansion of price limits. Provided by Well.
Growth 250 rebounds, space ventures are STAR = Emerging Markets, 17th.
The TSE Growth Market 250 Index rebounded. Buying focused on major stocks resulted in a steady trend. Space ventures such as Synspective <290A.T>, ispace <9348.T>, and Astroscale Holdings <186A.T> are STAR. Plaid <4165.T> and Heartsseed <219A.T> also saw increases. Trial Holdings <141A.T> and AI Robotics <247A.T> are low. In the standard category.
Advanced Reading Strategy Command Room = Heart Seed: Attention on the promising heart failure treatment progress, also gaining attention at the World Expo.
The biotech company Heartseed <219A.T> is likely to draw attention at the Osaka-Kansai Expo. It has developed "HS-001," which treats heart failure by injecting and transplanting allogeneic iPS cell-derived cardiomyocytes into the affected area through an open-heart surgery, regenerating and strengthening the cells to cure heart failure. Currently, there are 10 cases undergoing clinical trials, with 5 cases at a low dose and 5 cases at a high dose. The next generation product, "HS-005," will implant cardiomyocytes into the affected area via catheter without open-heart surgery, reducing the burden on patients.
Growth 250 plummeted, with declines in SanBio ETC = Emerging Markets, September 9.
The Tokyo Stock Exchange Growth Market 250 Index has sharply declined. Due to concerns over a trade war, there is a tendency for stock prices to drop again, with Emerging Markets also experiencing widespread losses. Major stocks such as Cover <5253.T> and SanBio <4592.T> have fallen. The drops of Genda <9166.T> and iSpace <9348.T> were also noticeable. Qualips <4894.T> and Heartseed <219A.T> have increased. In the Standard sector, Harmonic Drive Systems <6324.T> has reached new lows.
CellSeed - temporarily reached the upper limit, with a rapid rise in Qualisys expanding interest in drug discovery-related stocks.
The stock reached a temporary high. Qualips <4894> announced its application for manufacturing and selling regenerative medicine products derived from iPS cell-derived cardiac muscle cell sheets, which has led to a surge in buying interest, reaching a stop-high buying indication, expanding into drug discovery-related stocks. Besides Cellseed, K Pharma <4896> and Heartseed <219A> are also rapidly rising. Cellseed disclosed the start of clinical trials for allogenic cartilage cell sheets on March 24, which seems to be attracting renewed buying interest.
